Sohm Inc Stock Price, News & Analysis

SOHM, Inc. (OTCID:SHMN) announced the relocation of its operations to a new 24,000 square-foot commercialization facility in Vista, California. The strategic facility features a 50-50 split between office/lab space and warehouse space, designed to support manufacturing, R&D, and biotech commercialization activities.

Located at 1396 Poinsettia Avenue within the Poinsettia Business Park, this expansion aims to accelerate SOHM's growth strategy, support new product launches, and strengthen its presence in high-growth healthcare markets. The company expects the move to enhance operational efficiency, streamline product development, and facilitate new partnerships within Southern California's life sciences ecosystem.

SOHM (OTC:SHMN) has achieved a significant breakthrough in gene editing technology with its proprietary ABBIE platform version 2. The company successfully demonstrated that its advanced dCas12a domain can effectively modify human cells, enabling multi-target editing capabilities through crRNA arrays.

The company has also successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression, demonstrating immediate commercial applications in drug screening, research partnerships, and diagnostic development. This positions SOHM for strategic partnerships and licensing opportunities in the rapidly growing genome editing market, projected to reach $25 billion by 2030 with a CAGR of 16.1%.

SOHM Inc (OTC:SHMN), a pharmaceutical and biotechnology company, has launched its redesigned website at SOHM.com. The new website features improved navigation, enhanced product information, and comprehensive investor resources.

Key improvements include an intuitive user interface, detailed product ordering capabilities, updated information about their ABBIE genome editing platform, and expanded investor relations materials. Additionally, the company announced plans to launch an e-commerce platform at store.sohm.com in the coming days to support their B2C strategy for cosmeceuticals, nutraceuticals, and OTC products.

SOHM Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Ravi Kapoor as an Independent Director to its Board. Mr. Kapoor brings over 30 years of experience in corporate law, mergers and acquisitions (M&A), and financial management.

Mr. Kapoor currently serves as the proprietor of Ravi Kapoor & Associates and is a partner at Yan Advisory Services LLP and Amity Consultants LLP. His extensive qualifications include M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR. He has previously served on the boards of notable companies including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise).

SOHM (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced its strategic expansion into biotechnology-based cosmeceuticals. The company plans to leverage its biotech division to develop advanced skincare solutions incorporating biologically sourced actives such as exosomes, peptides, and regenerative proteins.

Under the guidance of Dr. Lucia Piccotti, SOHM's Cosmeceuticals expert and Health Advisory board member, the company will focus on cell culture and fermentation methods for producing high-purity cosmetic ingredients, along with advanced formulation strategies to enhance absorption, stability, and skin bioactivity. This initiative aligns with SOHM's strategic vision of expanding into high-value, innovation-focused product categories.

SOHM Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. Larissa Karnaoukhova as Vice President of Operations. Dr. Karnaoukhova brings significant credentials including a Ph.D. in Molecular Biology and an MBA, along with extensive experience in site operations management, sales, and business development. Her previous roles include Senior Director of Operations at Universal Sequencing Technology, where she managed manufacturing, quality control, and supply chain operations. At SOHM, she will focus on enhancing operational efficiency, leading QA/QC initiatives, FDA audits, process validations, and SOPs. The appointment aims to strengthen SOHM's operational capabilities and drive growth in the health sciences sector.

SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Lucia Piccotti, PhD, EMBA, to its advisory board to guide the development of cosmeceuticals and personal health products. Dr. Piccotti brings over a decade of experience in biomedical science and business leadership, having served as Senior Director of Strategic Innovation at Kiromic Biopharma and founder of Iguvia LLC, a cosmeceuticals consulting firm. Her background includes significant work at Kimberly-Clark Corporation and expertise in phytoextract-based topical applications. Dr. Piccotti holds a PhD in Biochemistry, focusing on liposomal delivery systems, an MS in Chemistry, and an Executive MBA. Her appointment aims to enhance SOHM's capabilities in developing innovative consumer health solutions.

SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary ABBIE™ platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.

The ABBIE™ platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.

SOHM Inc. (OTC:SHMN) has appointed Dr. Leonardo Mirandola as Advisory Board Member to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, previously served as CSO and Interim COO at Kiromic Biopharma, where he developed therapies including an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy for Stage 4 non-small cell lung cancer.

SOHM is leveraging its proprietary gene editing platform, ABBIE, to enhance CAR-T cell therapy commercialization. ABBIE offers advantages over traditional viral-based or CRISPR systems, including cost-efficiency, reduced manufacturing complexity, and fewer regulatory hurdles. The company aims to improve production timelines, genetic payload fidelity, and therapeutic window accessibility.